Evidence map›Paper›PMID 24430172›Full record

ArticleGenes and immunity

Variability in the CIITA gene interacts with HLA in multiple sclerosis.

A Gyllenberg, F Piehl, L Alfredsson, J Hillert, I L Bomfim, L Padyukov, M Orho-Melander, E Lindholm, M Landin-Olsson, Å Lernmark and 4 more

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Genes and immunity. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

A GyllenbergDepartment of Clinical Neuroscience, Neuroimmunology Unit, Karolinska Institutet, Stockholm, Sweden.
F PiehlDepartment of Clinical Neuroscience, Neuroimmunology Unit, Karolinska Institutet, Stockholm, Sweden.
L AlfredssonInstitute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
J HillertDepartment of Clinical Neuroscience, Multiple Sclerosis Research Group, Karolinska Institutet, Stockholm, Sweden.
I L BomfimDepartment of Clinical Neuroscience, Neuroimmunology Unit, Karolinska Institutet, Stockholm, Sweden.
L PadyukovDepartment of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden.
M Orho-MelanderDepartment of Clinical Sciences, Diabetes and Cardiovascular Disease, Genetic Epidemiology, Lund University Hospital, Lund, Sweden.
E LindholmDepartment of Clinical Sciences, Diabetes and Cardiovascular Disease, Genetic Epidemiology, Lund University Hospital, Lund, Sweden.
M Landin-OlssonDepartment of Endocrinology, Skane University Hospital Lund, Lund University, Lund, Sweden.
Å LernmarkDepartment of Medicine, Lund University Hospital, Lund, Sweden.
Swedish Childhood Diabetes Study Group
Diabetes Incidence in Sweden Study Group
T OlssonDepartment of Clinical Neuroscience, Neuroimmunology Unit, Karolinska Institutet, Stockholm, Sweden.
I KockumDepartment of Clinical Neuroscience, Neuroimmunology Unit, Karolinska Institutet, Stockholm, Sweden.
Karolinska Institutet · SELund University · SEUppsala University · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The human leukocyte antigen (HLA) is the main genetic determinant of multiple sclerosis (MS) risk. Within the HLA, the class II HLA-DRB1*15:01 allele exerts a disease-promoting effect, whereas the class I HLA-A*02 allele is protective. The CIITA gene is crucial for expression of class II HLA molecules and has previously been found to associate with several autoimmune diseases, including MS and type 1 diabetes. We here performed association analyses with CIITA in 2000 MS cases and up to 6900 controls as well as interaction analysis with HLA. We find that the previously investigated single-nucleotide polymorphism rs4774 is associated with MS risk in cases carrying the HLA-DRB1*15 allele (P=0.01, odds ratio (OR): 1.21, 95% confidence interval (CI): 1.04-1.40) or the HLA-A*02 allele (P=0.01, OR: 1.33, 95% CI: 1.07-1.64) and that these associations are independent of the adjacent confirmed MS susceptibility gene CLEC16A. We also confirm interaction between rs4774 and HLA-DRB1*15:01 such that individuals carrying the risk allele for rs4774 and HLA-DRB1*15:01 have a higher than expected risk for MS. In conclusion, our findings support previous data that variability in the CIITA gene affects MS risk, but also that the effect is modulated by MS-associated HLA haplotypes. These findings further underscore the biological importance of HLA for MS risk.

Indexed as

Epistasis, GeneticGenetic VariationAllelesCase-Control StudiesGene FrequencyGenotypeHLA AntigensHumansLinkage DisequilibriumMultiple SclerosisNuclear ProteinsOdds RatioPolymorphism, Single NucleotideTrans-ActivatorsHLA AntigensMHC class II transactivator proteinNuclear ProteinsTrans-Activators

Identifiers

PMID24430172
OpenAlexW2028243681

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.